ASCO 2024 Highlights
Wednesday, July 3, 2024
![ASCO 2024 Dr. Barve](https://marycrowley.org/wp-content/uploads/2024/06/ASCO-1.jpg)
MCCR Chief Medical Officer, Dr. Minal Barve at ASCO 2024
The American Society of Clinical Oncology (ASCO) held its 60th Annual Meeting in Chicago from May 31 to June 4, 2024, with more than 40,000 attendees from around the globe including both clinicians and professionals.
The meeting featured hundreds of sessions uplifting the theme of “The Art and Science of Cancer Care: From Comfort to Cure.” Thousands of abstracts, posters, publications and educational sessions were presented during the ASCO 2024 Annual Meeting, including several by Mary Crowley Cancer Research.
MCCR staff members and physicians had the opportunity to meet with representatives from more than 20 organizations including several key industry companies, patient advocacy groups and patient foundations. These meetings will be invaluable in exploring new collaborative opportunities for Mary Crowley Cancer Research.
MCCR contributed many abstract posters and four were selected for oral presentation. Review Mary Crowley Cancer Research’s contributions in abstracts, posters, presentations and videos, by clicking on the links below:
Dr. Minal Barve’s Contributions
Trial 19-09 – Phase 1 study of CTX-471, a novel CD137 agonist antibody, in patients with progressive disease following PD-1/PD-L1 inhibitors in metastatic or locally advanced malignancies.
Dr. Douglas Orr’s Contributions
Trial 23-08 – Safety and activity of Diakine DK210 (EGFR), a next-generation tumor-targeted IL2 x IL10 dual immunocytokine, in patients with advanced cancer: Initial results of the phase 1 first-in-human trial.
Dr. Reva Schneider’s Contributions
Trial 23-05 – Safety, pharmacokinetics (PK), pharmacodynamics (PD) and efficacy of KT-253, a targeted protein degrader of MDM2, in patients with relapsed/refractory (R/R) solid tumors, lymphoma, high grade myeloid malignancies and acute lymphoblastic leukemia (ALL).
The Mary Crowley Cancer Research team thanks all our patients, caregivers, staff members and referring oncologists for supporting MCCR and contributing to clinical research. Without the patients’ commitment, there would not be such amazing advances to share at conferences such as ASCO. HOPE LIVES HERE!